NDC 70121-1218-07 - Doxorubicin Hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70121-1218
- Requested NDC
- 70121-1218-07
- Package NDCs from labels
- 70121-1218-1, 70121-1218-7, 70121-1218-07
- Manufacturer
- Amneal Pharmaceuticals LLC
- Effective date
- 2024-05-29
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Doxorubicin Hydrochloride - Amneal Pharmaceuticals LLC | Amneal Pharmaceuticals LLC | 2024-05-29 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70121-1218-1 | Doxorubicin Hydrochloride | 1 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 1 | 12 | |
| 70121-1218-1 | Doxorubicin Hydrochloride | 10 mL in 1 VIAL | INJECTION, POWDER, LYOPHILIZED, | 10 | 12 | |
| 70121-1218-7 | Doxorubicin Hydrochloride | 10 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 10 | 12 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 70121-1218 | DOXORUBICIN HYDROCHLORIDE (DOXORUBICIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION DOXORUBICIN HYDROCHLORIDE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [AMNEAL PHARMACEUTICALS LLC] | 12 | Current NDC, Legacy NDC, 3 package rows | 20240830_d928625e-c1ef-4f25-8d25-764c8c6aab67.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | BluePoint Laboratories | 55889588-c5f1-d9bc-e063-6294a90a5791 | 2026-07-09 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin Hydrochloride | DOXORUBICIN HYDROCHLORIDE | BluePoint Laboratories | f6508535-e7a7-4e50-8d0c-43deda8d0d08 | 2026-05-21 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin Hydrochloride | DOXORUBICIN HYDROCHLORIDE | Pfizer Laboratories Div Pfizer Inc | 1fd148fb-0fbc-4b6f-b790-23546fb46a71 | 2026-05-05 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin Hydrochloride | DOXORUBICIN HYDROCHLORIDE | Pfizer Laboratories Div Pfizer Inc | 00634b2b-4e48-4178-8877-28582af894ad | 2026-04-30 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin Hydrochloride | DOXORUBICIN HYDROCHLORIDE | NorthStar RxLLC | ddf55319-bf62-4ec7-8be2-ef97188837c4 | 2026-04-10 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin Hydrochloride | DOXORUBICIN HYDROCHLORIDE | Sun Pharmaceutical Industries, Inc. | fbc48fa5-0bfb-4957-b13c-a56bb7a13b56 | 2026-04-06 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | BluePoint Laboratories | ada390ce-50ea-4de5-be58-5b03caf33c23 | 2026-03-27 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | Zydus Pharmaceuticals USA Inc. | 15a84bd6-b565-4722-bb92-e4c919620a90 | 2026-03-17 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| DOXIL | DOXORUBICIN HYDROCHLORIDE | Baxter Healthcare Corporation | 917eddf9-1d3f-4abe-8c81-d33b066e5bae | 2026-03-10 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin Hydrochloride Liposome | DOXORUBICIN HYDROCHLORIDE | Sagent Pharmaceuticals | c8eb4784-36e0-483f-9e5d-af0552e49bb5 | 2026-02-24 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | Lupin Pharmaceuticals, Inc. | 0f8eb9a1-74d0-47fd-94b8-a65b29006521 | 2025-11-30 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | Sagent Pharmaceuticals | ae80bd3a-b99a-4e01-a444-b9d05687f00e | 2025-07-01 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | Alembic Pharmaceuticals Limited | f8e001f5-441c-47cd-86f6-5d5e3de16bc0 | 2025-07-01 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin Hydrochloride | DOXORUBICIN HYDROCHLORIDE | Pfizer Laboratories Div Pfizer Inc | d31d7f58-66d0-4826-b6b5-5914c031965f | 2025-03-31 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | BluePoint Laboratories | b8b66e93-0813-4876-b291-8d7c36a99807 | 2024-12-11 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin Hydrochloride | DOXORUBICIN HYDROCHLORIDE | Fresenius Kabi USA, LLC | e0349f98-42fa-4003-b6d8-a1db1401b0ef | 2024-10-14 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin Hydrochloride | DOXORUBICIN HYDROCHLORIDE | Gland Pharma Limited | 74b14803-afc8-4a2e-ba92-43f1a72025eb | 2024-09-24 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | Actavis Pharma, Inc. | 33ddfdb1-b4bc-464d-a186-49c4b156279f | 2024-07-01 | Boxed warning, Warnings, Adverse reactions | 82F2G7BL4E |
| Doxorubicin Hydrochloride | DOXORUBICIN | Amneal Pharmaceuticals LLC | d928625e-c1ef-4f25-8d25-764c8c6aab67 | 2024-05-29 | Boxed warning, Warnings, Adverse reactions | ANDA208888 70121-1218-7 70121-1219-1 70121-1218-1 70121-1218 70121-1219 70121121807 1790095 1872062 f4a01f55-65d7-401f-ac2f-e1511bf3a429 d928625e-c1ef-4f25-8d25-764c8c6aab67 82F2G7BL4E |
| Doxorubicin Hydrochloride | DOXORUBICIN HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | f62aa88d-1e25-4049-87ec-99d42edd1d31 | 2024-04-26 | Boxed warning, Warnings, Adverse reactions | 1790095 82F2G7BL4E |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.